Posts tagged “Quintiles”
Quintiles beats Wall Street expectations in revenue and earnings with income topping $1.41 billion and profits of 69 cents per share. Plus, the world's largest life sciences services company projects growth of up to 16 percent per share in 2015.
Dennis Gillings, who co-founded Quintiles while he was a professor at UNC-Chapel Hill, plans to step down as the firm's chairman later this year. He will, however, remain a member of the board and "continue his close association" with the firm, Quintiles says.
Several North Carolina firms are at the forefront of developing new treatments for the Ebola virus, but they face challenges in testing and delivering them, executives from Chimerix, Quintiles and GlaxoSmithKline say at a conference in RTP.
Quintiles is named the top contract research organization for the third straight year in the prestigious annual SCRIP Awards. The SCRIP Awards are among the best-known in the life science industry, so much so that three N.C. firms are major sponsors. Check out the entire list of winners.
Quintiles' new service package; Intel's buy; Samsung exec stays; BlackBerry's encryption deal; EU pressures Google
In today's Bulldog wrapup of life science and technology news: Quintiles bundles a series of services for drug firms; Intel buys PasswordBox; Samsung keeps mobile business chief; BlackBerry signs encryption deal with Germany; and the EU steps up pressure on Google.
A new report says 895 clinical trials for new drugs targeting a wide variety of diseases are underway in North Carolina. But the "Research in Your Backyard" report says greater diversity in races, ages, sex and sexual orientation are needed.
Quintiles, Metabolon CEOs headline CED biotech conference; diversity in emojis?; AT&T hiring in Triangle; AT&T's big buy; YouTube amends copyright
In today's Bulldog wrapup of technology and life science news: The CEO of Quintiles along with the CEO of Metabolon headline the CED's biotech conference; Those emojis you like to use may soon come in colors; AT&T is hiring in Raleigh; AT&T making a big buy in Mexico; and YouTube amends copyright form.
Founder Dennis Gillings and other key investors are selling 13 million shares in Quintiles, and the world's largest life science services firm is buying $250 million of them through an underwriter. The deal means Quintiles' big investors now own less than 50 percent of the company and some changes in governance are coming as a result, a spokesperson says.
Quintiles CEO Tom Pike is on the lookout for more acquisitions. In a quarterly earnings conference call Thursday, Pike said the world's largest life science services company is on the "lookout" to put acquisition targets "under our wing." Our Insider subscribers get the details.
In the midst of the deadly Ebola outbreak and the rushing to trial of experimental treatments, the world's top life sciences services company is calling for faster drug and vaccine development. In a 21st Century Cures Initiative discussion hosted by Rep. Renee Ellmers on Thursday, the head of the Phase 1 Clinical Research Division at Quintiles, said Phase 1 trial "timelines" should be reduced by "addressing inefficiencies and redundancies." Quintiles has helped develop and commercialize all of the world's top 100 selling drugs in 2013.
Tom Pike, CEO of Quintiles, sees a new wave of business coming for life science services companies. And the world's largest contract research organization is ready to capitalize on "risk-based monitoring," he says in a conference call.
Quintiles, the world's largest life science company, says new business surged 21 percent in its most recent quarter, driving revenues to $1.035 billion compared to $944 million a year ago. Earnings jumped 30 percent to 65 cents per share. Quintiles also adjusted upward its financial expectations for the year.
In today's Bulldog wrapup of technology and life science news: Pozen resubmits a drug application; Amazon to fight FTC over kid apps purchases; Furiex and Quintiles deals close; Twitter names a new CFO
Contract research organizations aren't what they used to be. But, they are where they used to be: in North Carolina.
Quintiles CEO Tom Pike says Quintiles' ability to offer pharmas more than simply outsourced clinical trial services will lead to the company's growth. Read more about his comments to analysts and investors at Goldman Sach's healthcare conference.